Aqtual

Aqtual, Inc., a precision medicine company incorporated in Delaware, was founded in 2021 by Diana R. Abdueva, Ph.D., who serves as the CEO and Founder. Abdueva brings a wealth of experience to the venture, with a background that includes roles at Illumina and Grail, where she focused on product development and commercialization in the fields of liquid biopsy and oncology diagnostics. Her journey reflects a deep commitment to translating scientific research into practical healthcare applications, a core principle of Aqtual's mission.

The company operates in the biotechnology and healthcare sectors, specifically focusing on the development of diagnostic products for oncology and chronic diseases. Aqtual is leveraging a proprietary cell-free DNA (cfDNA) platform to create these products. This technology aims to provide early disease detection and monitor treatment response by analyzing small fragments of DNA circulating in the bloodstream. The initial focus is on creating a modular platform to support the development of various tests, starting with an application for head and neck cancer.

Aqtual's business model centers on developing and commercializing these precision medicine tests. The target clients are healthcare providers, pharmaceutical companies, and research institutions that require advanced diagnostic tools. By offering a less invasive method for disease management, the company aims to improve patient outcomes and streamline treatment protocols. The company has secured early-stage funding, including a pre-seed round, to advance its research and development efforts.

Keywords: precision medicine, cell-free DNA, oncology diagnostics, liquid biopsy, chronic disease management, biotechnology, head and neck cancer, cfDNA platform, early disease detection, healthcare diagnostics